These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Lomitapide: A novel agent for the treatment of homozygous familial hypercholesterolemia. Davis KA; Miyares MA Am J Health Syst Pharm; 2014 Jun; 71(12):1001-8. PubMed ID: 24865757 [TBL] [Abstract][Full Text] [Related]
5. Microsomal transfer protein inhibition in humans. Cuchel M; Rader DJ Curr Opin Lipidol; 2013 Jun; 24(3):246-50. PubMed ID: 23594709 [TBL] [Abstract][Full Text] [Related]
6. Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia. Blom DJ; Averna MR; Meagher EA; du Toit Theron H; Sirtori CR; Hegele RA; Shah PK; Gaudet D; Stefanutti C; Vigna GB; Larrey D; Bloedon LT; Foulds P; Rader DJ; Cuchel M Circulation; 2017 Jul; 136(3):332-335. PubMed ID: 28716835 [No Abstract] [Full Text] [Related]
7. Lomitapide for use in patients with homozygous familial hypercholesterolemia: a narrative review. Neef D; Berthold HK; Gouni-Berthold I Expert Rev Clin Pharmacol; 2016; 9(5):655-63. PubMed ID: 26943823 [TBL] [Abstract][Full Text] [Related]
8. Review of the long-term safety of lomitapide: a microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia. Khoury E; Brisson D; Roy N; Tremblay G; Gaudet D Expert Opin Drug Saf; 2019 May; 18(5):403-414. PubMed ID: 30945578 [TBL] [Abstract][Full Text] [Related]
9. Lomitapide, a microsomal triglyceride transfer protein inhibitor for the treatment of hypercholesterolemia. Rizzo M IDrugs; 2010 Feb; 13(2):103-11. PubMed ID: 20127562 [TBL] [Abstract][Full Text] [Related]
10. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis. Leipold R; Raal F; Ishak J; Hovingh K; Phillips H Eur J Prev Cardiol; 2017 Nov; 24(17):1843-1850. PubMed ID: 28925748 [TBL] [Abstract][Full Text] [Related]
11. Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia. Gouni-Berthold I; Berthold HK Atheroscler Suppl; 2015 May; 18():28-34. PubMed ID: 25936301 [TBL] [Abstract][Full Text] [Related]
12. Lomitapide for the management of homozygous familial hypercholesterolemia. deGoma EM Rev Cardiovasc Med; 2014; 15(2):109-18. PubMed ID: 25051128 [TBL] [Abstract][Full Text] [Related]
13. Use of microsomal triglyceride transfer protein inhibitors in patients with homozygous familial hypercholesterolemia: translating clinical trial experience into clinical practice. Toth PP; Shah PK; Wilkinson MJ; Davidson MH; McCullough PA Rev Cardiovasc Med; 2014; 15(1):1-10. PubMed ID: 24762461 [TBL] [Abstract][Full Text] [Related]
14. Case report: The efficacy and safety of lomitapide in a homozygous familial hypercholesterolemic child. Chacra APM; Ferrari MC; Rocha VZ; Santos RD J Clin Lipidol; 2019; 13(3):397-401. PubMed ID: 30948303 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of hepatic microsomal triglyceride transfer protein - a novel therapeutic option for treatment of homozygous familial hypercholesterolemia. Vuorio A; Tikkanen MJ; Kovanen PT Vasc Health Risk Manag; 2014; 10():263-70. PubMed ID: 24851052 [TBL] [Abstract][Full Text] [Related]
20. Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia. Perry CM Am J Cardiovasc Drugs; 2013 Aug; 13(4):285-96. PubMed ID: 23720215 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]